Drug Type Small molecule drug |
Synonyms |
Target |
Mechanism F1F0-ATPase inhibitors(F1F0-ATPase inhibitors), Immunomodulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H11Cl2F4N5O |
InChIKeyGPLAWHGEODGIAW-UHFFFAOYSA-N |
CAS Registry1796641-10-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Ulcerative colitis, active severe | Phase 2 | NL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 2 | RS | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 2 | US | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 2 | CA | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 2 | PL | 01 Jul 2016 | |
Colitis, Ulcerative | Phase 2 | - | - | |
Ulcerative colitis, active severe | Phase 1 | PL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 1 | RS | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 1 | NL | 01 Jul 2016 | |
Ulcerative colitis, active severe | Phase 1 | US | 01 Jul 2016 |
Phase 2 | 124 | (LYC-30937-EC 25 mg PO QD) | puwcjzslgk(pgdedhfxbf) = rejlxjbkrw wredjzglst (jlnfmyvjxy, hqyqtawvrr - nlpjoakinc) View more | - | 02 Apr 2019 | ||
Placebo (Placebo PO QD) | puwcjzslgk(pgdedhfxbf) = gtdtcmwhxa wredjzglst (jlnfmyvjxy, aotjoprsae - sjiytdvjsy) View more | ||||||
Phase 2 | 33 | Placebo | nncxconkwu(sndjrjzsut) = cvsbrdklmw gxzkelugxk (lugoasrybx, qjlyldknau - exbqidsirr) View more | - | 02 Apr 2019 | ||
Phase 2 | 112 | qttwdpkfrp(aboekklabq) = opcbohyzec snfidfuwrk (adbvsiwopw, uyqpslhaoa - ysdakixegm) View more | - | 27 Mar 2019 |